IRVING, Texas, Oct. 3 /PRNewswire-FirstCall/ -- Carrington Laboratories, Inc. today announced that Dr. Yawei Ni, Chief Scientific Officer of DelSite Biotechnologies, Inc., Carrington’s wholly-owned subsidiary, will make an key presentation titled “An Effective Adjuvant Based on a Novel In-situ Gelling Anionic Polysaccharide (GelSite(R) Polymer)” on November 13, 2007, at the second International Conference on Modern Vaccines/Adjuvants Formulation (MVAF) in Dublin, Ireland.
GelSite(R) polymer is a chemically and functionally distinct polygalacturonic acid (sodium salt) produced under cGMP to a purity of > 99%. It is uniquely capable of gelling in-situ at the administration site upon contact with body fluids at low polymer concentrations providing a sustained release mechanism of the active component. It is highly suited for the delivery of vaccines and therapeutics.
The presentation will discuss details of GelSite(R) polymer’s immunoenhancing and antigen sparing effect following intramuscular injection. The GelSite(R) polymer is inert and non-immunostimulatory, but achieves its immunoenhancing and antigen-sparing effect through sustained release of vaccine antigens conferred by the in-situ gelation. It potentially represents a new class of adjuvants that act through the sustained release mechanism, rather than by immunostimulation.
Vaccines, one of the fast growing pharmaceutical segments, are projected to account for greater than $20 billion in sales in the next few years. Adjuvants are a critical component for vaccine development. Vaccines in a wide range of areas including infectious diseases and cancers are being developed by various companies, many of which will require adjuvants for optimal performance.
About MVAF 2007
MVAF 2007 will be an international forum for researchers and contributors from academic programs, industrial, governmental and regulatory groups interested in the future development and design of vaccines and adjuvants. The scientific program will include keynote lectures, contributed papers, workshops, panel discussions and poster presentations emphasizing all aspects of the usage and effectiveness of pharmaceutical development of vaccines and adjuvants, national and international regulatory guidelines, and safety issues with special emphasis on delivery/administration issues.
About DelSite
Carrington’s wholly-owned subsidiary DelSite Biotechnologies, Inc., is developing its proprietary GelSite(R) technology designed to provide controlled release of peptide and protein-based drugs and vaccines. DelSite is currently developing a nasal powder vaccine using its GelVac(TM) formula with the H5N1 avian flu antigen. This work is partially funded by two grants from NIAID (National Institute of Allergy and Infectious Diseases) of NIH (National Institute of Health) under the Department of Health and Human Services.
About Carrington
Carrington Laboratories, Inc. is an ISO 9001-certified, research-based, biopharmaceutical and consumer products company currently utilizing naturally-occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care, as well as to manufacture and market the nutraceutical raw material Manapol(R) and cosmetic raw material Hydrapol(TM). Carrington also manufactures and markets consumer products and manufactures quality products for other companies. Manufacturing operations comply with cGMP standards. Carrington’s technology is protected by more than 130 patents in 26 countries. Select products carry the CE mark, recognized by more than 20 countries around the world. For more information, visit http://www.carringtonlabs.com.
Certain statements in this release concerning Carrington may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to: subsequent changes in plans by the Company’s management; delays or problems in formulation, manufacturing, distribution, production and/or launch of new finished products; changes in the regulatory process; changes in market trends; and a number of other factors and risks described from time to time in the Company’s filings with the Securities & Exchange Commission.
CONTACT: Carlton E. Turner, Chief Executive Officer of Carrington
Laboratories, Inc., +1-972-518-1300
Web site: http://www.carringtonlabs.com/
